A pilot study of the CMV inSIGHT T-cell immunity panel to assess cytomegalovirus (CMV) cell mediated immunity (CMI) in allogeneic hematopoietic cell transplant (HCT) recipients [0.03%]
CMV inSIGHT T细胞免疫检测试验评估同种异体造血细胞移植(HCT)受者细胞介导的抗巨细胞病毒(CMV)免疫能力的研究
Swarn Arya,Rich Kodama,Yuxuan Li et al.
Swarn Arya et al.
Background: Cytomegalovirus T-cell mediated immunity (CMV CMI) is essential for CMV control after allogeneic hematopoietic cell transplantation (HCT). Clinical experience with commercially available CMV CMI assays in lete...
Periodontitis therapy using autologous adipose-derived stromal cells: a double-blind randomized controlled clinical trial in an aged canine model [0.03%]
自体脂肪源性基质细胞治疗牙周炎的双盲随机对照临床试验——老龄犬模型研究
Paul Monsarrat,Sara Laurencin-Dalicieux,Géraldine Jourdan et al.
Paul Monsarrat et al.
Background aims: The aim of this randomized double-blind trial was to assess the biosafety and efficacy of cell therapy by adipose-derived stromal cells (ASCs) in a suitable hydrogel biomaterial to improve clinical and bi...
Quadruple immunotherapy with allogeneic natural killer cell infusion for recurrent neuroblastoma [0.03%]
复发性神经母细胞瘤的四联免疫疗法联合同种异体自然杀伤细胞输注治疗
Chi Hang Wong,Man Yan Hui,Wilson Yau Ki Chan et al.
Chi Hang Wong et al.
Background aims: Relapsed/refractory (R/R) neuroblastoma remains lethal despite multi-modality therapy. We evaluated a quadruple immunotherapy regimen combining haploidentical natural killer (NK) cell infusion, dinutuxima...
Yeast surface display meets immunotherapy: unlocking the potential of T cells [0.03%]
酵母表面展示技术助力免疫治疗：解锁T细胞的潜力
Jie Wang,Yukun Li,Jinglong Shi et al.
Jie Wang et al.
Background aims: While T-cell receptors (TCRs) hold immense therapeutic potential, their clinical translation is bottlenecked by the scarcity of high-affinity, specific clones and the instability of recombinant formats. E...
AI-driven quality control of cell-based ATMPs: automated, accurate, and affordable [0.03%]
基于细胞的先进治疗药物制造中的人工智能驱动的质量控制：自动化、精确且经济高效
Rasmus Magnusson,Alice Hägg,Daniel Twohig et al.
Rasmus Magnusson et al.
Background aims: The production of neuroepithelial stem (NES) cells, a promising therapeutic candidate for neurological conditions such as stroke and spinal cord injuries, faces significant manufacturing challenges, parti...
In-house manufacture of plasma-derived human AB serum for use in cellular therapeutics [0.03%]
用于细胞治疗的血浆源性人AB型胎盘 cord 血清的内部制备方法
Paige O Mirsky,John Lister,Albert D Donnenberg
Paige O Mirsky
Successful manufacture of cellular therapeutic products requires a medium containing key nutrients to support cell expansion. Some of the most common supplements to cell culture media include serum products such as fetal bovine serum, human...
Preclinical evaluation of a novel CD4 specific CAR NK cell therapy for T-cell malignancies [0.03%]
用于T细胞恶性肿瘤的新型CD4特异性CAR-NK细胞治疗的临床前评估
Katharina Eva Ruppel,Philipp Lückemeier,Alexander Scholz et al.
Katharina Eva Ruppel et al.
Background: T-cell leukemias and lymphomas (TCL) are a rare and heterogeneous group of cancers with limited treatment options and an overall poor prognosis. In contrast to B-cell malignancies, the development of cellular ...
Umbilical cord mesenchymal stromal cells for respiratory complications of COVID-19 infection (ProTrans): phase II randomized clinical trial [0.03%]
用于COVID-19感染呼吸并发症的胎盘间充质干细胞临床试验（ProTrans）：二期随机对照试验
Inés Colmegna,Marie Hudson,Lucie Biard et al.
Inés Colmegna et al.
Background: Severe COVID-19 is characterized by an aberrant immune response leading to systemic inflammation, organ dysfunction and high mortality among hospitalized patients. Mesenchymal stromal cells (MSCs), due to thei...
Impact of Blinatumomab and Inotuzumab Exposure on Apheresis Composition for CAR T in Patients With B-cell Acute Lymphoblastic Leukemia [0.03%]
Blinatumomab和Inotuzumab暴露对B细胞急性淋巴细胞白血病患者CAR-T组份采集的影响
Anna Cantilena,Kyu Lee Han,Yihua Cai et al.
Anna Cantilena et al.
Children with B-cell acute lymphoblastic leukemia (B-ALL) are increasingly treated with immunotherapeutic agents such as blinatumomab and inotuzumab. Thus, those who present in relapse for chimeric antigen receptor (CAR) T-cell therapy are ...
Real-world outcomes of Axicabtagene Ciloleucel CAR-T therapy in large B-cell lymphoma: a single-center observational study [0.03%]
阿基仑赛治疗大B细胞淋巴瘤的真实世界结果——一项单中心观察性研究
Khalid Alsuhaibani,Amal Hejab,Maha Aljasser et al.
Khalid Alsuhaibani et al.
Background: Axicabtagene Ciloleucel (Axi-cel) has recently transformed the treatment landscape for relapsed or refractory large B-cell lymphoma (R/R LBCL). Despite promising results in pivotal trials like ZUMA-1 and ZUMA-...